Biotechnology - Pfizer


Current filters:


Popular Filters

1 to 25 of 66 results

BioRestorative Therapies enters research accord with Pfizer


US stem-cell therapies developer BioRestorative Therapies has entered into a two-year collaborative research…

BioRestorative TherapiesBiotechnologyLicensingMetabolicsPfizerResearch

Actelion says COMPASS-2 bosentan study fails primary endpoint

Actelion says COMPASS-2 bosentan study fails primary endpoint


Europe’s largest biotech company Actelion has announced disappointing results of COMPASS-2, a Phase…

ActelionBiotechnologybosentanPfizerResearchRespiratory and PulmonarysildenafilTracleer

Systemic psoriasis market forecast to reach $10.4 billion by 2020


The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Puma Biotech rockets on positive results with neratinib in I-SPY 2 TRIAL


USA-based development-stage firm Puma Biotechnology saw its shares leap 42% to nearly $66 in morning…

BiotechnologyneratinibOncologyPfizerPuma BiotechResearch

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA


Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Gliknik enters licensing agreement with Pfizer


Gliknik has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, which is…

BiotechnologyGliknikImmunologicalsLicensingNorth AmericaOncologyPfizer

Oxford BioMedica earns Pfizer milestone


UK, gene-based biopharma company Oxford BioMedica (LSE: OXB) says it has received a $1 million milestone…

BiotechnologyFinancialOncologyOxford BioMedicaPF-06263507PfizerResearch

Onyx Pharma accepts increased bid from Amgen


Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

Lonza and BioWa sign research agreement with Pfizer


Swiss chemicals and drug company Lonza (SIX: LONN) and USA-based BioWa, a wholly-owned subsidiary of…


Ligand enters global license deal for women's health product


Ligand Pharmaceuticals (Nasdaq: LGND) announces the signing of a global license agreement with recently-formed…

Azure BiotechBiotechnologyGloballasofoxifeneLicensingLigand PharmaceuticalsPfizerPharmaceuticalWomen's Health

New EULAR recommendations address use of synthetic and biological DMARDs


The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Onyx Pharma rejects Amgen's unsolicited $120 per share takeover offer


Following a day of speculation and rumor on Friday, US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX)…

AmgenBayerBiotechnologyCelgeneMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizerRoche

CytomX signs up to $635 million oncology deal with Pfizer


US biotech firm CytomX Therapeutics, which is developing a new generation of targeted antibody therapeutics,…

BiotechnologyCytomX TherapeuticsLicensingOncologyPfizerPharmaceuticalResearch

World's first long-lasting hemophilia therapies will see Biogen move ahead of Pfizer and Baxter


As US biotech company Biogen Idec (Nasdaq: BIIB) prepares to break into the hemophilia market by launching…

BaxterBiogen IdecBiotechnologyMarkets & MarketingPfizerPharmaceutical

Appeals Court rules against EMD Serono over Rebif deal with Pfizer


Germany's Merck KGaA (MRK: DE) says that a Pennsylvania appeals court has ruled against Merck in deciding…

BiotechnologyEMD SeronoLegalMarkets & MarketingMerck KGaANeurologicalNorth AmericaPfizerPharmaceuticalRebif

BIND Therapeutics in $50M deal with Pfizer, plus $160M per Accurins milestone


US clinical stage, investor backed biopharma company BIND Therapeutics has entered into a global collaboration…

AccurinsBIND TherapeuticsBiotechnologyLicensingOncologyPfizerPharmaceuticalResearch

1 to 25 of 66 results

Company Spotlight



Back to top